The American Journal of Managed Care12h
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
Shuttle Pharma hits 25% mark in glioblastoma trial
GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a specialty pharmaceutical company with a current ...
pharmaphorum3y
Failed trial nixes another FDA approval, this time for BMS' Istodax
The HDAC inhibitor was given an accelerated approval ... It's the third time in recent months that BMS has trimmed down the uses for its cancer drugs, coming after it withdrew approvals for ...
FierceBiotech26d
Cash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining options
In early November, Viracta said it would be waving goodbye to 42% of its remaining staff in order to keep money flowing to its lead program, a combination of the HDAC inhibitor nanatinostat and ...
BioWorld29d
Suzhou Puhe Biopharma divulges new CoREST/HDAC complex inhibitors
Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...
Business Insider13d
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company’s Oncology Pipeline
The claims also include combination therapies comprising use of the hedgehog pathway inhibitors along with an HDAC inhibitors enhancing anti-cancer efficacy. “Issuance of the new patent for our ...
Medindia4d
CG Pharmaceuticals: Progress of U.S. Phase 1b/2 Metastatic Pancreatic Cancer Clinical Trial at the ASCO Gastrointestinal Symposium
CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity in 2024 after licensing ivaltinostat ...